Latest News about RHHBY
Recent news which mentions RHHBY
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
October 06, 2021
From Benzinga
Moderna Is Down 12%. Is It Time to Buy?
October 06, 2021
From Motley Fool
Why Novavax Stock Plunged in September
October 06, 2021
From Motley Fool
Which COVID-19 Pill Stock Is the Best Buy?
October 05, 2021
From Motley Fool
2 Best Biotech Stocks to Buy In October
October 04, 2021
From Motley Fool
3 Stocks That Might Soar With Pills for COVID
October 03, 2021
From Motley Fool
Here Are the Leaders in the Race to Develop a COVID-19 Pill
October 03, 2021
From Motley Fool
From Benzinga
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
October 01, 2021
From Benzinga
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
September 30, 2021
From Benzinga
3 COVID Stocks Ready to Take On the Delta Variant
September 27, 2021
From Motley Fool
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
September 27, 2021
From Benzinga
3 Biotech Stocks That Could Make You Filthy Rich
September 27, 2021
From Motley Fool
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
From Benzinga
September Sell-Off Alert: Buy Vertex Pharmaceuticals on the Dip
September 25, 2021
From Motley Fool
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients
September 24, 2021
From Benzinga
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
September 24, 2021
From Benzinga
Here's Why Everyone's Talking About AstraZeneca Right Now
September 21, 2021
From Motley Fool
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
September 20, 2021
From Benzinga
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
September 18, 2021
From Motley Fool
Why Adaptimmune Therapeutics Was Sinking This Week
September 17, 2021
From Motley Fool
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
From Benzinga
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
September 15, 2021
From Benzinga
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
September 14, 2021
From Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
From Benzinga
These OTCQX & OTCQB Securities Had the Most Trading Activity in August
September 13, 2021
From Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
September 12, 2021
From Benzinga
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
September 10, 2021
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.